Literature DB >> 19636261

Serum sodium predicts prognosis in critically ill cirrhotic patients.

Chang-Chyi Jenq1, Ming-Hung Tsai, Ya-Chung Tian, Ming-Yang Chang, Chan-Yu Lin, Jau-Min Lien, Yung-Chang Chen, Ji-Tseng Fang, Pan-Chi Chen, Chih-Wei Yang.   

Abstract

BACKGROUND: End-stage liver disease is often complicated by hyponatremia. Cirrhotic patients with hyponatremia admitted to intensive care units (ICUs) have high mortality rates. This study analyzed the outcomes of critically ill cirrhotic patients and identified the prognostic value of serum sodium concentration.
METHODS: One hundred twenty-six consecutive cirrhotic patients admitted to the ICU of a tertiary center during a 1.5-year period were enrolled in this study. Demographic, clinical, and laboratory variables on the first day of ICU admission were prospectively recorded for post hoc analysis.
RESULTS: Overall hospital mortality was 65.1%. Comparing with serum sodium >135 mmol/L, patients with serum sodium <or=135 mmol/L had a greater frequency of ascites, illness severity scores, hepatic encephalopathy, sepsis, renal failure, and in-hospital mortality (55.9% vs. 73.1%, P=0.043). Multiple Cox proportional hazards analysis revealed that serum sodium levels, hepatocellular carcinoma, and sequential organ failure assessment scores on the first day of ICU admission were independent risk factors for 6-month mortality. Cumulative survival rates at 6-month follow-up after hospital discharge differed significantly (P<0.05) between patients with serum sodium >135 mmol/L versus those with serum sodium <or=135 mmol/L.
CONCLUSIONS: Low serum sodium levels in critically ill cirrhotic patients are associated with high complications of liver cirrhosis, in-hospital mortality, and poor short-term prognosis. The serum sodium concentration is important predictor of survival among candidates for liver transplantation. Future research with sequential application of serum sodium may reflect the dynamic aspects of clinical conditions, thus providing complete data for mortality risk.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19636261     DOI: 10.1097/MCG.0b013e3181aabbcd

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  23 in total

1.  Hyponatremia and Its Correlation With Hepatic Encephalopathy and Severity of Liver Disease.

Authors:  Amna Younas; Junaid Riaz; Tamoor Chughtai; Hamza Maqsood; Muhammad Saim; Shaheryar Qazi; Shifa Younus; Umar Ghaffar; Muhammad Khaliq
Journal:  Cureus       Date:  2021-02-06

Review 2.  Mild Chronic Hyponatremia in the Ambulatory Setting: Significance and Management.

Authors:  Helbert Rondon-Berrios; Tomas Berl
Journal:  Clin J Am Soc Nephrol       Date:  2015-06-24       Impact factor: 8.237

3.  Hyponatremia Is Protective Against the Development of Portal Vein Thrombosis in Patients Undergoing Liver Transplant.

Authors:  Dmitri Bezinover; Seyedehsan Navabi; Ming Wang; Zheng Li; Meryl William; Jonathan G Stine
Journal:  Transplant Proc       Date:  2019 Jul - Aug       Impact factor: 1.066

4.  Factors that predict short-term intensive care unit mortality in patients with cirrhosis.

Authors:  Ranjeeta Bahirwani; Marwan Ghabril; Kimberly A Forde; Hemant Chatrath; Karen M Wolf; Lindsay Uribe; K Rajender Reddy; Barry Fuchs; Naga Chalasani
Journal:  Clin Gastroenterol Hepatol       Date:  2013-04-16       Impact factor: 11.382

5.  Hepatocellular carcinoma treated by conventional transarterial chemoembolization in field-practice: serum sodium predicts survival.

Authors:  Marco Biolato; Luca Miele; Vittoria Vero; Simona Racco; Carmine Di Stasi; Roberto Iezzi; Andrea Zanché; Maurizio Pompili; Gian Ludovico Rapaccini; Giuseppe La Torre; Antonio Gasbarrini; Antonio Grieco
Journal:  World J Gastroenterol       Date:  2014-07-07       Impact factor: 5.742

6.  Hyponatremia at discharge as a predictor of 12-month clinical outcomes in hospital survivors after acute myocardial infarction.

Authors:  Myung Hwan Bae; Jae Hee Kim; Se Yong Jang; Sun Hee Park; Jang Hoon Lee; Dong Heon Yang; Hun Sik Park; Yongkeun Cho; Shung Chull Chae
Journal:  Heart Vessels       Date:  2016-06-02       Impact factor: 2.037

7.  The end-organ impairment in liver cirrhosis: appointments for critical care.

Authors:  Antonio Figueiredo; Francisco Romero-Bermejo; Rui Perdigoto; Paulo Marcelino
Journal:  Crit Care Res Pract       Date:  2012-05-16

8.  Improving survival in decompensated cirrhosis.

Authors:  Amar Nath Mukerji; Vishal Patel; Ashokkumar Jain
Journal:  Int J Hepatol       Date:  2012-07-02

Review 9.  Hyponatremia in cirrhosis and end-stage liver disease: treatment with the vasopressin V₂-receptor antagonist tolvaptan.

Authors:  Paul Gaglio; Kwaku Marfo; Joseph Chiodo
Journal:  Dig Dis Sci       Date:  2012-06-26       Impact factor: 3.199

Review 10.  Step by Step: Managing the Complications of Cirrhosis.

Authors:  Irene C Perez; Fabian J Bolte; William Bigelow; Zachary Dickson; Neeral L Shah
Journal:  Hepat Med       Date:  2021-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.